{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:54:48Z","timestamp":1784548488453,"version":"3.55.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102568","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:36:00Z","timestamp":1601984160000},"page":"102568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["CNS demyelination during tofacitinib therapy: First report"],"prefix":"10.1016","volume":"46","author":[{"given":"Fathi","family":"Massoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-7044","authenticated-orcid":false,"given":"Ismail Ibrahim","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasem Y.","family":"Al-Hashel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-8254","authenticated-orcid":false,"given":"Hesham","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msard.2020.102568_bib0001","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.4049\/jimmunol.160.6.2742","article-title":"Induction of Jak\/STAT signaling by activation of the type 1 TNF receptor","volume":"160","author":"Guo","year":"1998","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2020.102568_bib0002","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/1352458519894710","article-title":"Pathological findings in central nervous system demyelination associated with infliximab","volume":"26","author":"Kalinowska-Lyszczarz","year":"2020","journal-title":"Mult. Scler."},{"issue":"8","key":"10.1016\/j.msard.2020.102568_bib0003","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1016\/j.msard.2020.102568_bib0004","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2020.102568_bib0005","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/j.1552-4604.1992.tb04635.x","article-title":"Advances in the diagnosis of adverse drug reactions","volume":"32","author":"Naranjo","year":"1992","journal-title":"J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.msard.2020.102568_bib0006","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1242\/jcs.00963","article-title":"The JAK\/STAT signaling pathway","volume":"117","author":"Rawlings","year":"2004","journal-title":"J. Cell. Sci."},{"key":"10.1016\/j.msard.2020.102568_bib0007","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: a report of two cases","author":"Rotstein","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1016\/j.msard.2020.102568_bib0008","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2011.12.156","article-title":"Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation","volume":"418","author":"Yoshida","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.msard.2020.102568_bib0009","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5021537","article-title":"Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17\/Treg Balance","volume":"2016","author":"Zhou","year":"2016","journal-title":"J. Immunol. Res."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820306428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:32Z","timestamp":1761900752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820306428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":9,"alternative-id":["S2211034820306428"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102568","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS demyelination during tofacitinib therapy: First report","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102568"}}